Wells Fargo analyst David Maris noted that an update posted on June 18 by the FDA revealed that a Paragraph IV challenge of Bausch Health's Bryhali was filed on March 20. The analyst, who explained that a Paragraph IV filing is made when a generic filer asserts either non-infringement or invalidity of branded product patents, called Bryhali one of Bausch's "key new drugs," noting that the company included it in what it has dubbed its "Significant Seven" products. A Paragraph IV filing does not mean a generic is imminent, said Maris, who also noted that such filings often result in settlements. The analyst, who said he is awaiting a reply from Bausch about this situation and whether it has sued the filing company, keeps an Underperform rating on Bausch Health shares.